These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Estramustine phosphate versus stilbestrol as primary treatment for metastatic cancer of the prostate. Nickel CJ; Morales A Can J Surg; 1983 Sep; 26(5):434-8. PubMed ID: 6351988 [TBL] [Abstract][Full Text] [Related]
23. Continuous versus intermittent oral therapy with estramustine phosphate (Estracyt). Vahlensieck W; Wegner G Scand J Urol Nephrol Suppl; 1980; 55():147-9. PubMed ID: 6938018 [TBL] [Abstract][Full Text] [Related]
24. [Treatment of hormone-resistant prostate cancer with estramustine phosphate (Estracyt)]. Stridsklev IC; Fosså SD; Kaalhus O Tidsskr Nor Laegeforen; 1984 Oct; 104(28):1977-80. PubMed ID: 6388019 [No Abstract] [Full Text] [Related]
25. A randomized double blind crossover trial of diethylstilbestrol (DES) and estramustine phosphate (Emcyt) for stage D prostatic carcinoma. Benson RC; Gill GM; Cummings KB Semin Oncol; 1983 Sep; 10(3 Suppl 3):43-5. PubMed ID: 6364366 [No Abstract] [Full Text] [Related]
26. Relationship of prior hormonal therapy to subsequent estramustine phosphate treatment in advanced prostatic cancer. Slack NH; Wajsman Z; Mittelman A; Bruno S; Murphy GP Urology; 1979 Dec; 14(6):549-54. PubMed ID: 390810 [TBL] [Abstract][Full Text] [Related]
27. Metabolic parameters of Estracyt pertinent to its effects in prostatic cancer. Sandberg AA Urology; 1984 Jun; 23(6 Suppl):11-21. PubMed ID: 6375075 [No Abstract] [Full Text] [Related]
28. [Plasma changes caused by estrogens in the vascular risk of prostatic carcinoma over a 3-year period]. Daponte DP; Stevens I; Robinson MR Actas Urol Esp; 1986; 10(6):437-40. PubMed ID: 3825644 [No Abstract] [Full Text] [Related]
29. The EORTC Phase III trials in prostatic cancer. Robinson MR; Smith PH; Macaluso MP; Sylvester R; de Voogt H Prog Clin Biol Res; 1985; 185A():243-9. PubMed ID: 3898132 [No Abstract] [Full Text] [Related]
30. [Serum testosterone and acid phosphatase levels in patients with prostatic cancer treated with Estracyt]. Németh A; Morvay J; Vécsei B Orv Hetil; 1981 Apr; 122(17):1017-20. PubMed ID: 7022313 [No Abstract] [Full Text] [Related]
31. Treatment of prostatic carcinoma with estramustine phosphate (Estracyt). Benson RC Wis Med J; 1976 Sep; 75(9):S89-90. PubMed ID: 969557 [No Abstract] [Full Text] [Related]
32. Treatment of advanced prostatic carcinoma with estramustine phosphate (Estracyt). Jönsson G; Högberg B; Nilsson T Scand J Urol Nephrol; 1977; 11(3):231-8. PubMed ID: 339329 [TBL] [Abstract][Full Text] [Related]
33. Combined therapy of advanced prostatic carcinoma with estramustine and prednimustine. Catane R; Kaufman J; Mittelman A; Murphy GP J Urol; 1977 Mar; 117(3):332-5. PubMed ID: 839597 [TBL] [Abstract][Full Text] [Related]
34. Estramustine phosphate therapy in carcinoma of the prostate. Andersson L; Edsmyr F; Jönsson G; Könyves I Recent Results Cancer Res; 1977; (60):73-7. PubMed ID: 866798 [TBL] [Abstract][Full Text] [Related]
35. [Treatment of advanced carcinoma of the prostate with Estracyt (author's transl)]. Nagel R; Kölln CP Med Klin; 1976 Oct; 71(41):1724-8. PubMed ID: 824540 [TBL] [Abstract][Full Text] [Related]
36. [Use of Estracyt in cases of prostatic neoplasms]. Wesolowski S; Czaplicki M; Cieślak A Pol Przegl Chir; 1976 Jun; 48(6A):783-9. PubMed ID: 951325 [No Abstract] [Full Text] [Related]